Browsing by Author "Garrido, Marta"

Sort by: Order: Results:

  • Constitutive Cyclin O deficiency results in penetrant hydrocephalus, impaired growth and infertility
    Núñez Ollé, Marc, 1984-; Jung, Carole; Terré, Berta; Balsiger, Norman A.; Plata, Cristina; Roset i Huguet, Ramon; Pardo Pastor, Carlos; Garrido, Marta; Rojas, Santiago; Alameda Quitllet, Francisco; Lloreta Trull, Josep, 1958-; Martín Caballero, Juan; Flores, Juana M.; Stracker, Travis; Valverde, M. A. (Miguel Ángel), 1963-; Muñoz López, Francisco José, 1964-; Gil Gómez, Gabriel (Impact Journals, 2017)
    Cyclin O (encoded by CCNO) is a member of the cyclin family with regulatory functions in ciliogenesis and apoptosis. Homozygous CCNO mutations have been identified in human patients with Reduced Generation of Multiple ...
  • Extracellular Granzyme A promotes colorectal cancer development by enhancing gut inflammation
    Santiago, Llipsy; Gil Gómez, Gabriel; Garrido, Marta; Peña, Raúl; Pardo, Julián (Elsevier, 2020)
    If not properly regulated, the inflammatory immune response can promote carcinogenesis, as evident in colorectal cancer (CRC). Aiming to gain mechanistic insight into the link between inflammation and CRC, we perform ...
  • miR-24-3p regulates CDX2 during intestinalization of cardiac-type epithelium in a human model of Barrett's esophagus
    Gil Gómez, Gabriel; Fassan, Mateo; Nonell Mazelón, Lara; Garrido, Marta; Climent Agustín, Marta Carmen; Anglada Busquets, Roger; Iglesias Coma, Mar; Guzzardo, Vicenza; Borga, Chiara; Grande Posa, Luís; Bolós, Carme de; Pera Roman, Manuel Ramón (Oxford University Press, 2021)
    Background: Cardiac-type epithelium has been proposed as the precursor of intestinal metaplasia in the development of Barrett's esophagus. Dysregulation of microRNAs (miRNAs) and their effects on CDX2 expression may ...
  • Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma
    Gallardo Hernández, Fernando; Bertran, Joan; López Arribillaga, Erika, 1986-; González, Jessica; Menéndez, Silvia; Sánchez Güerri, Ignacio; Colomo Saperas, Luis Alberto; Iglesias Coma, Mar; Garrido, Marta; Santamaría-Babí, Luis Francisco; Torres, Ferran; Pujol Vallverdú, Ramon Maria; Bigas Salvans, Anna; Espinosa Blay, Lluís (Nature Publishing Group, 2018)
  • p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
    Solé, Laura; Lobo-Jarne, Teresa; Álvarez-Villanueva, Daniel; Alonso-Marañón, Josune; Guillén, Yolanda; Guix Arnau, Marta, 1974-; Sangrador, Irene; Rozalén, Catalina; Vert, Anna; Lop Gros, Joan; Salido Galeote, Marta; Bellosillo Paricio, Beatriz; García-Romero, Raquel; Garrido, Marta; González, Jessica; López Arribillaga, Erika, 1986-; Iglesias Coma, Mar; Celià-Terrassa, Toni; Bigas Salvans, Anna; Espinosa Blay, Lluís (Nature Research, 2022)
    Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and ...
  • Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion
    Cantero Recasens, Gerard, 1984-; Alonso-Marañón, Josune; Lobo-Jarne, Teresa; Garrido, Marta; Iglesias Coma, Mar; Espinosa Blay, Lluís; Malhotra, Vivek (eLife, 2022)
    Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy. We now formally show that CRC cells build a barrier ...
  • Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
    Rivas, Elisa; Linares Aceituno, Jenniffer Lissethe; Zwick, Melissa; Gómez-Llonín, Andrea; Guiu, Marc; Labernadie, Anna; Badia-Ramentol, Jordi; Lladó, Anna; Bardia, Lídia; Pérez-Núñez, Iván; Martínez-Ciarpaglini, Carolina; Tarazona, Noelia; Sallent-Aragay, Anna; Garrido, Marta; Celià-Terrassa, Toni; Burgués, Octavio; Gomis, Roger R.; Albanell Mestres, Joan; Calon, Alexandre (Nature Research, 2022)
    About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two ...